Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics is seeing promise in an obesity drug. The company said it plans another phase 1 trial, as well as a phase 2 trial of VK2735.

Why Shares of Viking Therapeutics Skyrocketed This Week

SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $250.0 million.

Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Akero Therapeutics Inc

89bio Inc

Intercept Pharma

Eli Lilly

Madrigal Pharmaceuticals

Novo Nordisk

Pfizer

Terns Pharmaceuticals

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

Viking (VKTX) Announces Clinical Data for Metabolic Disorders

Viking Therapeutics stock has already gained an astounding 463% in the past six months. With key data readouts in obesity and NASH on tap later this year, the small-cap biotech could represent a once-in-a-lifetime opportunity for risk-tolerant investors.

Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run

Viking Therapeutics announced promising results on Tuesday from a phase 1 study of obesity drug VX2735. If VK2735 goes on to win approval, it should have a huge market opportunity.

Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the treatment of obesity. Viking Therapeutics develops novel therapies for metabolic and endocrine disorders.

Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

Viking said Tuesday recipients of its potential obesity treatment lost up to 18 pounds, and VKTX stock launched to a five-year high. The post Viking Therapeutics Steps Into The Obesity Ring — And Catapults 63% appeared first on Investor's Business Daily.

Viking Therapeutics Steps Into The Obesity Ring — And Catapults 63%

Viking Therapeutics (NASDAQ:VKTX) shares had added more than 55% on Tuesday after the biopharmaceutical company published positive early-stage data for its drug candidate targeting obesity VK2735. The company said in the multiple ascending doses (MAD) portion of the study, it observed up to 6% placebo-adjusted mean weight loss, 7.8% from baseline, after 28 days.

Viking Therapeutics shares up more than 50% on positive trial results for obesity drug

Viking Therapeutics Inc (NASDAQ:VKTX) is surging, last seen up 53.7% at $14.02, after the company revealed plans to start a mid-stage trial for experimental obesity drug VK2735 later this year.

Biotech Stock Surges to 4-Year Highs on Upbeat Trial

Viking Therapeutics (NASDAQ: VKTX ) stock is climbing higher on Tuesday after initiating a Phase 1 clinical trial of VK2735. VK2735 is a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist.

Why Is Viking Therapeutics (VKTX) Stock Up 38% Today?

Shares of Viking Therapeutics Inc. VKTX, +3.05% soared about 45% in premarket trading on Tuesday after the company said it started a Phase 1 clinical trial evaluating an oral version of its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. The experimental therapy is being tested as a treatment for obesity.

Viking's stock rallies as it announces trial for oral version of obesity drug

Expands Potential Opportunities for VK2735 with Highly Differentiated Dosing Option Data Anticipated in 2H2023 SAN DIEGO , March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735. The study, which is an extension of the company's recently completed Phase 1 evaluation of subcutaneously administered VK2735, will evaluate daily oral doses for 28 days.

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study Phase 2 Trial in Obesity Planned for Mid-2023 SAN DIEGO , March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735. The compound is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders.

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

Shares of Viking Therapeutics fell 25.2% during the week that ended March 24. Viking Pharmaceuticals fell in sympathy with Adaptimmune, which is developing a similar anti-obesity medication.

Is Viking Therapeutics a Smart Buy on the Dip?

Biotech name Viking Therapeutics is going back into the spotlight for the first time in nearly a year in today's focus article. Thanks mainly to promising results from a competitor in the NASH space, the shares have soared more than 150% since December.

Viking Therapeutics: Some Caution Warranted

These two NASH drugmakers have a lot of room to run.

2 Surging Healthcare Stocks That Are Still Worth Buying

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ET Company Participants Stephanie Diaz - Investor Relations Brian Lian - President and Chief Executive Officer Gregory Zante - Chief Financial Officer Conference Call Participants Joon So Lee - Truist Securities Steven Seedhouse - Raymond James & Associates Joseph Pantginis - H.C. Wainwright Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Scott Henry - ROTH MKM Partners Justin Zelin - BTIG Nazibur Rahman - Maxim Group Operator Welcome to the Viking Therapeutics Fourth Quarter and Full-year 2022 Financial Results Conference Call.

Viking Therapeutics, Inc. (VKTX) Q4 2022 Earnings Call Transcript

Conference call scheduled for 4:30 p.m. ET today Data from Three Clinical Programs Expected in 2023 Enrollment Completed in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in 2Q 2023 Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Continues; Data Expected in 1Q 2023 SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the SVB Securities Global Biopharma Conference.

Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

Conference Call Scheduled for Wednesday, February 8 at 4:30 p.m. Eastern Time SAN DIEGO , Feb. 1, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2022, after the market close on Wednesday, February 8, 2023.

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023

Cano Health

Carvana

Hall of Fame Resort & Entertainment

Nine Energy Service

PDS Biotechnology Corporation

Rayonier Advanced Materials

Silvergate Capital Corp

Summit Therapeutics

TuSimple Holdings

The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).

5 Best and Worst Performing Small-Cap Stocks in Q4 2022

Alset EHome International

CymaBay Therapeutics

Fate Therapeutics

Century Therapeutics

P3 Health Partners Inc

Avidity Biosciences

Trean Insurance Group

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Doses for up to 52 Weeks; Data for Primary Endpoint Expected in First Half of 2023 SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The company expects to report data for the study's primary endpoint in the first half of 2023.

Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

News for Viking Therapeutics Stock (VKTX)